Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalen...
Main Authors: | Stephanie Pepin, Jean-François Nicolas, Henryk Szymanski, Isabel Leroux-Roels, Thomas Schaum, Marc Bonten, Giancarlo Icardi, Anju Shrestha, Cynthia Tabar, The QHD00011 study team |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1983387 |
Similar Items
-
Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
by: Viviane Gresset-Bourgeois, et al.
Published: (2018-01-01) -
Development of the quadrivalent live attenuated influenza vaccine including two influenza B lineages – Victoria and Yamagata
by: Yu. A. Desheva, et al.
Published: (2016-02-01) -
Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
by: David P. Greenberg, et al.
Published: (2017-09-01) -
Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial
by: Joyce Ojeda, et al.
Published: (2020-06-01) -
An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
by: Anna Fochesato, et al.
Published: (2022-08-01)